Globus Medical Inc  

(Public, NYSE:GMED)   Watch this stock  
Find more results for GMED
15.22
-0.14 (-0.91%)
May 24 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 15.17 - 15.50
52 week 10.26 - 19.93
Open 15.50
Vol / Avg. 202,091.00/477,409.00
Mkt cap 1.40B
P/E 18.57
Div/yield     -
EPS 0.82
Shares 92.07M
Beta     -
Inst. own 40%
May 15, 2013
Globus Medical Inc at Bank of America Merrill Lynch Health Care Conference
May 7, 2013
Globus Medical Inc at Mizuho Securities USA Inc. (MSUSA) Healthcare Access Day
May 2, 2013
Q1 2013 Globus Medical Inc Earnings Conference Call - Webcast
Mar 19, 2013
Globus Medical Inc at Canaccord Genuity Musculoskeletal Conference
Feb 27, 2013
Q4 2012 Globus Medical Inc Earnings Conference Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '13) 2012
Net profit margin 18.94% 19.13%
Operating margin 27.83% 29.74%
EBITD margin - 34.23%
Return on average assets 17.33% 19.02%
Return on average equity 20.08% 22.07%
Employees 810 -
Carbon Disclosure Rating - -

Address

Valley Forge Business Center 2560 General Armistead Avenue
AUDUBON, PA 19403
United States - Map
+1-610-9301800 (Phone)
+1-610-9302042 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Globus Medical, Inc. (Globus) is a medical device company focused on the design, development and commercialization of products that promote healing in patients with spine disorders. As of December 31, 2011, the Company had launched over 110 products and offers a portfolio of products addressing a range of spinal pathologies, anatomies and surgical approaches. The Company's products fall into one of two categories: Innovative Fusion or Disruptive Technologies. The Company's Innovative Fusion products address a range of spinal fusion surgical procedures. Spinal fusion is a surgical procedure to correct problems with the individual vertebrae, the interlocking bones making up the spine, by preventing movement of the affected bones. In July 2012, the Company acquired the assets of a small company with operations in the United States and Germany, including a new product designed to treat vertebral compression fractures (VCFs).

Officers and directors

David C. Paul Chairman of the Board, Chief Executive Officer
Age: 46
Bio & Compensation  - Reuters
David M. Demski President, Chief Operating Officer, Director
Age: 55
Bio & Compensation  - Reuters
Richard A. Baron CPA Chief Financial Officer, Senior Vice President
Age: 51
Bio & Compensation  - Reuters
A. Brett Murphy Executive Vice President, US Sales
Age: 48
Bio & Compensation  - Reuters
David D. Davidar Vice President - Operations, Director
Age: 47
Bio & Compensation  - Reuters
Daniel T. Lemaitre Independent Director
Age: 59
Bio & Compensation  - Reuters
Robert W. Liptak Independent Director
Age: 49
Bio & Compensation  - Reuters
Ann D. Rhoads Independent Director
Age: 47
Bio & Compensation  - Reuters
Kurt C. Wheeler Independent Director
Age: 60
Bio & Compensation  - Reuters